Etavopivat

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Conditions

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Trial Timeline

Nov 15, 2022 → Jul 15, 2024

NCT ID

NCT05568225

About Etavopivat

Etavopivat is a phase 2 stage product being developed by Novo Nordisk for Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R. The current trial status is terminated. This product is registered under clinical trial identifier NCT05568225. Target conditions include Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R.

What happened to similar drugs?

2 of 5 similar drugs in Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R were approved

Approved (2) Terminated (1) Active (2)

❌Roxadustat + PlaceboAstellas PharmaPhase 3

🔄Benralizumab Arm A + Benralizumab Arm B + PlaceboAstraZenecaPhase 3

🔄Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + PlaceboAstraZenecaPhase 3

✅BAY207543 (Bepanthol, Bepantol® Derma Spray)BayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06581627	Phase 1	Completed	Aug 26, 2024	Oct 31, 2024	Healthy Volunteers
NCT06433661	Phase 1	Completed	May 28, 2024	Jul 8, 2024	Healthy Volunteers Sickle Cell Disease, Thalassemia
NCT06336018	Phase 1	Completed	May 20, 2024	Aug 1, 2025	Liver Diseases
NCT05725902	Phase 2	Active	Mar 25, 2024	Feb 26, 2026	Sickle Cell Disease
NCT06198712	Phase 2	Recruiting	Jan 12, 2023	Aug 8, 2029	Sickle Cell Disease
NCT05568225	Phase 2	Terminated	Nov 15, 2022	Jul 15, 2024	Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Competing Products

10 competing products in Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

See all competitors

Product	Company	Stage	Hype Score
Roxadustat + Placebo	Astellas Pharma	Phase 3	32
Benralizumab Arm A + Benralizumab Arm B + Placebo	AstraZeneca	Phase 3	40
Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo	AstraZeneca	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ipilimumab	Bristol Myers Squibb	Phase 1/2	24
BAY207543 (Bepanthol, Bepantol® Derma Spray)	Bayer	Approved	40
BAY207543 (Bepanthol, Bepantol® Derma Spray)	Bayer	Approved	40
triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
Chondrogen + Chondrogen + Placebo	Mesoblast	Phase 1/2	26
Mesenchymal Stem Cells + Hyaluronan	Mesoblast	Phase 1/2	26